Brief: Brickell Biotech Reports Fourth Quarter, Full Year 2021 Financial Results

Fresh Tracks Therapeutics

15/03/2022 11:39

March 15 (Reuters) - Brickell Biotech Inc  BBI.O :
    * BRICKELL BIOTECH REPORTS FOURTH QUARTER AND FULL YEAR
2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
    * Q4 REVENUE $104,000
    * NEW DRUG APPLICATION (NDA) SUBMISSION TO U.S. FDA FOR
SOFPIRONIUM BROMIDE GEL, 15% EXPECTED IN MID-2022
    * ON TRACK TO INITIATE PHASE 1 STUDY FOR BBI-02 FOR
TREATMENT OF
AUTOIMMUNE AND INFLAMMATORY DISEASES IN Q2 2022
    * TOPLINE RESULTS FROM SAD AND MAD PARTS OF PHASE 1 STUDY
ANTICIPATED YEAR-END 2022
    * REPORTED CASH AND CASH EQUIVALENTS OF $26.9 MILLION AS OF
DECEMBER 31, 2021, COMPARED TO $30.1 MILLION AS OF DECEMBER 31,
2020
    * EXPECTS ITS CASH AND CASH EQUIVALENTS WILL SUPPORT
OPERATIONS
BEYOND RECEIPT OF PHASE 1 SAD AND MAD TOPLINE RESULTS FOR BBI-02
    * QTRLY LOSS PER SHARE $0.06
    * Q4 EARNINGS PER SHARE VIEW $-0.09, REVENUE VIEW $154750.00
--
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3Xkff6 
Further company coverage:  BBI.O